You are here

Article Text

Article menu
Download PDFPDF
Uterine Cancer
Uterine Leiomyosarcoma: An Updated Series
  1. Jose Alejandro Rauh-Hain, MD*,
  2. Titilope Oduyebo, MD*,†,
  3. Elisabeth J. Diver, MD*,†,
  4. Stephanie H. Guseh, MD*,†,
  5. Suzanne George, MD‡,
  6. Micheal G. Muto, MD† and
  7. Marcela G. del Carmen, MD, MPH*
  1. *Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital;
  2. †Division of Gynecologic Oncology, Brigham and Women’s Hospital; and
  3. ‡Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.
  1. Address correspondence and reprint requests to Marcela G. del Carmen, MD, MPH, Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, 55 Fruit St, Yawkey 9 E, Boston, MA 02114. E-mail: mdelcarmen@partners.org.

Abstract

Objective The aim of this study was to analyze and compare the clinicopathologic characteristics, treatment, and survival in patients with uterine leiomyosarcoma (ULMS) during the last 10 years in 3 referral academic centers.

Methods All patients with ULMS who underwent treatment at the participating institutions between January 1, 2000, and December 31, 2010, were identified from the tumor registry database. In each case, the diagnosis was confirmed by a dedicated gynecologic pathologist following postsurgery pathology review. The Kaplan-Meier method was used to generate overall survival (OS) data. Factors predictive of outcome were compared using the log-rank test and Cox regression analysis.

Results Analysis of 167 women with ULMS with adequate follow-up was performed. One hundred twenty-eight patients (77%) were initially managed at the participating institutions, and 39 (23%) were referred after initial management at a different institution. Ninety-two (55%) had stage I disease, 7 (4%) had stage II, 18 (11%) stage III, and 50 (30%) had stage IV disease. The median OS for women with stage I was 75 months, for stage II 66 months, stage III 34 months, and stage IV 20 months (P < 0.001). For patients with early stage (I and II), race, lower grade, smaller tumor size (<11 cm), low number of mitosis (<25/10 high-power field [HPF]), lymphovascular space invasion, and presence of necrosis were identified as variables with prognostic influence on survival in the univariate analysis. A Cox proportional hazards model identified size 11 cm or greater (hazard ratio, 5.9; P < 0.001) and mitotic count of 25/10 HPF or greater (hazard ratio, 2.3; P = 0.05) as independent predictors of OS. For patients with late stage (stage III and IV), race, stage III versus IV, lower grade, smaller tumor size (<11 cm), and low number of mitosis (<25/10 HPF) were all associated with significantly improved OS. A Cox proportional hazards model identified mitotic count of 25/10 HPF or greater (P = 0.01) as independent predictor of OS.

Conclusions In early stage, size of the tumor and number of mitosis were associated to survival. In contrast to late stage, only mitotic count was associated to survival.

  • Uterine leiomyosarcoma
  • Chemotherapy
  • Radiotherapy

https://doi.org/10.1097/IGC.0b013e31829590dc

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • The authors declare no conflicts of interest.